Chemo Neuropathy News 2026: 7 Real Updates (and What Is Still Hype)

Numb, tingling or burning hands and feet are one of the most common reasons people struggle through cancer treatment, and one of the reasons doses get lowered or stopped. Because the need is so great, this is also a field full of loud promises. Real progress looks quieter: a small trial in a medical journal, a conference abstract with caveats, or a lab result that is years from patients.

This page lists what genuinely changed for chemotherapy-induced peripheral neuropathy (CIPN) in 2026, in order of how close it is to helping you. For every item we give the date, where it was published, whether it was tested in people or animals, and whether you can use it today. It is a companion to our guide to chemotherapy-induced neuropathy, which explains which drugs cause it and how long it lasts. If you are in treatment, every decision below belongs with your oncology team.

1. Cooling the Feet or Applying Compression During Chemo Lowered Neuropathy in Two 2026 Trials

Status: ask your infusion team; early evidence in people. Both trials were published in the January 2026 issue of Clinical Breast Cancer. Tested in people.

In the first, 120 patients with stage I to III breast cancer receiving paclitaxel-based chemotherapy were randomly assigned to standard care or standard care plus continuous foot cooling: an adjustable wrap kept at 13 to 16 °C, started 30 minutes before the infusion and left on until 15 minutes after. Neuropathy scores in the lower limbs were lower in the cooling group at 6 weeks (21.58 vs 26.28), 12 weeks (22.75 vs 28.56) and 3 months after treatment (19.73 vs 26.65). The authors calculated that about 7 patients would need cooling for 1 to benefit.

The second trial enrolled 108 breast cancer patients who had already developed neuropathy after their first cycle of albumin-bound paclitaxel. They received standard care alone or with compression at one of two pressure levels (23 to 32 mmHg or 34 to 46 mmHg). After three cycles there was no difference between groups. After five cycles, both compression groups had less neuropathy than standard care, and the higher-pressure group did best.

Two caveats matter. The cooling trial was open-label, meaning patients and staff knew who was cooled, and neuropathy was scored on a patient questionnaire, which expectations can influence. And both are single trials in breast cancer; the cooling authors themselves wrote that larger multicenter trials are needed.

What it means for you: some cancer centers already offer frozen gloves and socks or compression garments during taxane infusions, as we describe in our chemo neuropathy guide. These trials add support, but not proof for every drug or cancer. Do not improvise this at home: numb skin can miss a cold injury or a garment that is too tight, so ask your infusion team to set it up and monitor it.

2. Two 2026 Reviews Back Exercise and Acupuncture, but They Disagree on the Details

Status: usable now with your team’s approval; evidence is mixed. Published February 9, 2026 in Supportive Care in Cancer and August 2026 in the European Journal of Oncology Nursing. Pooled results of trials in people.

The February network meta-analysis combined 27 randomized trials with 2,136 patients, searched through October 2025. It found that physical exercise beat medication on a neurotoxicity score (mean difference −9.9) and that acupuncture improved nerve symptoms and neuropathic pain, and was linked to a lower rate of CIPN developing.

The August analysis used 32 trials (1,612 patients), 19 of which fed the ranking, and was more cautious. Only acupuncture-based treatment significantly reduced pain compared with controls. Cryotherapy ranked highest on a statistical scale and exercise came second, but neither showed a statistically significant pain reduction, and the results varied widely between trials. The authors wrote that the effectiveness of cryotherapy and exercise “remains unclear.”

Two other 2026 papers add nuance. An April review in the Journal of Pain Research of 13 studies (638 patients, mostly colorectal cancer) found that multimodal exercise, combining endurance, strength and balance, reduced CIPN severity, while aerobic exercise alone did not, and only 3 of the 13 studies were rated strong quality. A September 10 review of acupuncture in Frontiers in Neurology noted that sham-controlled results “are not uniformly positive.”

What it means for you: exercise that mixes strength, balance and endurance, ideally through a cancer rehabilitation or physical therapy referral, is a reasonable thing to ask for, especially if numb feet make you unsteady. Acupuncture can cause bruising or bleeding, which matters if chemotherapy has lowered your blood counts, so tell your team first. Our guide to exercises for neuropathy covers the general principles.

3. Gabapentin Users Had More Neuropathy in Two ASCO 2026 Studies, and That Is Not What It Seems

Status: not a treatment finding; do not change medication. Two conference abstracts presented at the American Society of Clinical Oncology (ASCO) annual meeting, May 29 to June 2, 2026, published in the Journal of Clinical Oncology supplement. Records of people.

The first looked at 565 adults who received neurotoxic chemotherapy at a multi-hospital health system between July 2025 and January 2026. Neuropathy was documented in 36.3% of those who also took gabapentin or pregabalin versus 16.7% of those who did not, a relative risk of 2.17. The gap was widest with taxane drugs (42.2% vs 15.5%). With platinum drugs the difference (30.8% vs 20.4%) was not statistically clear. The second abstract analyzed 594,148 hospital records from 2017 to 2021 and found gabapentin exposure linked to CIPN codes (adjusted odds ratio 1.37). In the same analysis, a coded vitamin B12 deficiency was linked to CIPN too (adjusted odds ratio 2.17).

The authors themselves explain the catch. In the first study, “the timing of gabapentinoid initiation relative to neuropathy onset cannot be determined, so causal inference is limited.” In the second, the link is “likely reflecting its use for neuropathic symptom management.” In plain words: doctors prescribe these drugs to people who already have nerve symptoms, so they naturally appear more often in the neuropathy group.

What it means for you: this does not show that gabapentin causes neuropathy, and it does not show that it prevents or treats it. The most recent ASCO guideline we found, from 2020, says duloxetine is the only drug with appropriate evidence for established painful CIPN, and that its benefit is limited. If you take a gabapentinoid, keep taking it as prescribed and raise questions at your next visit. Conference abstracts are also shorter and less thoroughly reviewed than journal papers.

4. Online Therapy for Painful CIPN Missed Its Main Goal in a New Trial

Status: unclear; we could not confirm the program is available outside the study. Published September 2026 in Psycho-Oncology. Tested in people.

The Embrace Pain trial enrolled 112 cancer survivors who had lived with painful CIPN for at least six months after chemotherapy. Half were assigned to an 8-week guided online program based on acceptance and commitment therapy (ACT), a skills-based approach to living with pain; the other half were put on a waiting list. On the main measure, how much pain interferes with daily life, the program did not significantly outperform the waiting list.

There were small signs of something. At three months, 47.4% of the ACT group showed a clinically meaningful improvement in pain interference versus 23.6% of the waiting list, and exploratory analyses showed pain catastrophizing (dwelling on pain and expecting the worst) falling more in the ACT group. But pain intensity, CIPN severity and quality of life did not differ between groups.

What it means for you: this is not a way to heal nerves, and it is not proven for pain itself. It is an honest negative-leaning result with a hint that some people may cope better. If persistent pain is wearing you down, a psycho-oncology or pain-psychology referral is a legitimate conversation, and the authors say larger studies are needed.

5. Oral Vitamin B12 Looked Protective in a Very Small Trial

Status: not recommended on this evidence. Published May 2026 in the Asian Pacific Journal of Cancer Prevention. Tested in 40 people; patients were enrolled in 2021.

At one hospital, 40 patients with gynecological cancers were randomly given 500-microgram vitamin B12 tablets or placebo tablets from the start of chemotherapy until four weeks after six cycles. Neuropathy, by a patient questionnaire, appeared in 5% of the B12 group versus 20% of the placebo group. That is 1 patient against 4. A quality-of-life neuropathy score showed no difference between the groups, and no safety differences appeared.

The authors conclude B12 “may be recommended as a preventive measure,” but a trial this small cannot carry that conclusion. The ASCO guideline reconfirmed in 2020 that no agents are recommended for preventing CIPN, and it advised against acetyl-L-carnitine specifically.

What it means for you: do not start B12 or any supplement during chemotherapy on the strength of this. A true B12 deficiency is a different matter, because it can cause neuropathy by itself, and it is reasonable to ask whether your level should be checked. Our article on vitamin B12 and nerve pain explains who is at risk and what the evidence shows.

6. Two Pills Tested in 2026: Memantine Eased CIPN Pain, High-Dose Selenium Mostly Did Not

Status: not available for CIPN; doctor-only decisions. Published in BMJ Supportive & Palliative Care (April 2026) and BMC Medicine (February 2026). Tested in people.

Memantine is an existing prescription drug approved for Alzheimer’s disease that blocks a receptor involved in pain signaling. In a double-blind trial of 176 people with CIPN, half took memantine, built up to 20 mg a day, and half took a matching placebo for 8 weeks. The memantine group improved more on a pain questionnaire and on a tuning-fork vibration test, and a larger share reached a clinically meaningful improvement. The measures were limited, the abstract reports mostly p-values, and we found no second trial that repeats it, so treat it as promising, not settled. Using it for nerve pain would be off-label.

High-dose selenium was tested by intravenous infusion in 68 patients with recurrent ovarian cancer, given before each paclitaxel-carboplatin-bevacizumab cycle. The main goal, fewer patients with any CIPN at 3 months, was not met. A secondary result did favor selenium: grade 2 or worse motor dysfunction before cycle 3 was 3.3% versus 23.3%. There was no extra toxicity and no difference in survival, but the authors call it a pilot and the benefit is only a hint.

What it means for you: neither is a treatment. Selenium here was given by infusion in a hospital, so it is not something to copy with a store-bought supplement, and selenium pills have their own limits and risks. Both results mainly tell researchers where to look next.

7. Psilocybin Prevented Chemo Nerve Damage in Mice; a Human Trial Is Planned

Status: lab stage; Phase 2 human trial not yet recruiting. Published September 3, 2026 in Science. Tested in mice.

Researchers at MD Anderson Cancer Center, led by Moran Amit and Patrick Dougherty, tested psilocybin, the active compound in “magic mushrooms,” in mouse models of CIPN using cisplatin, paclitaxel and docetaxel across repeated chemotherapy cycles. According to the center, “as few as two doses of psilocybin given before chemotherapy prevented hypersensitivity to cold, protected sensory nerve endings and preserved touch sensation,” while keeping the chemotherapy’s anticancer activity. The proposed mechanism is that psilocybin, acting on serotonin 5-HT2A receptors, keeps mitochondria, the cell’s energy packs, moving along nerve fibers after chemotherapy.

That is genuinely interesting, because no drug is currently recommended to prevent CIPN. The center states that the work is preclinical, with no human data. A Phase 2 trial called NeuroGuard is registered on ClinicalTrials.gov: an estimated 83 people with breast, colorectal or head and neck cancer, three groups (four supervised 25 mg doses, a 1 mg low dose, or standard care), listed as not yet recruiting, with an estimated start of November 4, 2026 and an estimated primary completion in January 2029.

What it means for you: nothing for now. Most treatments that work in mice do not work in people, and this trial will not report for years. Psilocybin is not an approved way to protect your nerves, and it is not something to try on your own, least of all during chemotherapy.

What Should You Ask Your Oncology Team Now?

Most of this year’s news is early. The practical takeaways are questions, not purchases:

• Do you offer cooling or compression for my chemotherapy drug? Ask before the first infusion if you can, because these approaches are meant to be used during treatment.
• Can we check my nerves at every visit? ASCO guidance says clinicians should weigh delaying, reducing, substituting or stopping chemotherapy when neuropathy becomes intolerable or limits function, so describe numbness, balance trouble and trouble with buttons or handwriting early.
• Could I be referred to an exercise or rehabilitation program? Multimodal exercise (strength, balance and endurance together) is the best-supported exercise option in this year’s reviews.
• If pain develops, is duloxetine appropriate for me? It is the one drug with guideline support for established painful CIPN.
• Should my vitamin B12 level be checked? A confirmed deficiency is worth correcting; a normal level is not helped by extra.
• Is there a clinical trial I could join? Search your cancer type and “peripheral neuropathy” on ClinicalTrials.gov, the free U.S. government registry, and bring any match to your team.

For the wider picture, including how long CIPN lasts and the self-care that protects your hands and feet, see our chemo neuropathy guide. If you want to see how nerve-pain research looks outside cancer care, our companion list of new neuropathy treatments in 2026 covers diabetic nerve pain.

Frequently Asked Questions